Compare GMRS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMRS | ASMB |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.0M | 512.1M |
| IPO Year | 2026 | 2010 |
| Metric | GMRS | ASMB |
|---|---|---|
| Price | $11.17 | $20.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $18.63 | ★ $52.00 |
| AVG Volume (30 Days) | ★ 726.6K | 199.6K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.13 | N/A |
| Revenue Next Year | $5.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.00 | $19.30 |
| 52 Week High | $15.98 | $39.71 |
| Indicator | GMRS | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 35.67 |
| Support Level | $9.75 | $19.30 |
| Resistance Level | $14.14 | $21.93 |
| Average True Range (ATR) | 0.51 | 1.02 |
| MACD | 0.19 | 0.26 |
| Stochastic Oscillator | 74.45 | 23.05 |
GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.